News
![BMS_sign](https://pharmaphorum.com/wp-content/uploads/2020/05/BMS_sign.jpg)
BMS swoops on Forbius, snaring another immuno-oncology playe...
With the ink barely dry on a deal to develop Dragonfly’s lead cancer immunotherapy, Bristol-Myers Squibb’s business development team has agreed to buy Canadian biotech Forbius